DUET Study (2018) — Trial Summary
DUET Study (2018): Evaluated the efficacy of sparsentan, a dual endothelin and angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS).
References
- Trachtman H, Nelson P, Adler S, et al. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745-2754.